What if we found cancer early enough to make a difference?

Priority Health is excited to provide access to the Galleri® multi-cancer early detection test from GRAIL. The test is available, for a copay, to PriorityMedicareSM Thrive and PriorityMedicareSM Thrive Plus members that meet the eligibility requirements.

The Galleri test is a proactive blood test that screens for many deadly cancers before symptoms appear.1,2,3 It screens for a “fingerprint” of 50+ cancers including many without recommended screening available today.1

Check Eligibility and Request the Test

Galleri is available by prescription only. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Roger testimonial

Galleri is available by prescription only. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Who is eligible?

The Galleri test is available to eligible Priority Health Medicare Advantage members* who meet the eligibility requirements. The Galleri test is available by prescription only. 

Eligibility requirements:

  • Individuals 65 years or older who are actively enrolled in one of the following Priority Health Medicare plans:
     
    • PriorityMedicare Thrive - $150 copay (a value of $799)
    • PriorityMedicare Thrive Plus - $75 copay (a value of $874)
  • Not currently undergoing active cancer treatment, though history of cancer^ with treatments completed at least 3 years ago is permitted

AND must also have AT LEAST ONE of the following clinical risk factors:

  • Diagnosis of HPV
  • Currently smokes or history of smoking
  • Elevated body mass index
    • Female ≥ 30 kg/m2
    • Male ≥ 35 kg/m2

* Eligible members can request the Galleri test once every two years.

^ excludes basal or squamous cell carcinoma of the skin

Important – For this program, the Galleri test cost is included as part of your copay if you request the test from an independent telemedicine provider at Recuro Health. The Galleri blood draw is also included with your copay if it is completed with a GRAIL partner laboratory (i.e. Quest, ExamOne, etc.). If you choose to complete the blood draw at another lab or office, you will be responsible for the blood draw fee. This program does not cover or pay for follow-up consults and diagnostic procedures (e.g., imaging, biopsies, other laboratory tests, etc.) that your healthcare provider may recommend for you in the event of a “Cancer Signal Detected” Galleri test result. You may incur cost-share expenses such as copays, deductibles, coinsurance. Please contact your health insurer to determine covered expenses and your potential costs related to follow-up procedures that your provider may recommend.

Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them

Our testing process

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Request the test

Get started by creating a Galleri portal account and completing an online test request which includes questions about your medical history (about 10 minutes). Use your insurance information. By requesting the test and completing the questionnaire, you're requesting a prescription from Recuro Health, an independent telemedicine provider.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Receive a collection kit

If the Recuro Health telemedicine physician confirms you are eligible and orders Galleri, you will receive a notification via email. Then, you can schedule a blood draw at one of GRAIL’s blood draw partners. You will receive a collection kit in the mail to take with you to your appointment.

illustrated graphic of a white, gray haired female patient having her blood drawn

Provide your sample

The trained technician that draws your blood sample will ship the kit to the GRAIL lab.

Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

Recuro Health will reach out when your results are ready — about 2 weeks after your blood is received at the GRAIL laboratory. Your test result will be shared with you by Recuro Health.

Important – For this program, the Galleri test cost is included as part of your copay if you request the test from an independent telemedicine provider at Recuro Health.

The Galleri blood draw is also included with your copay if it is completed with a GRAIL partner laboratory (i.e. Quest, ExamOne, etc.). If you choose to complete the blood draw at another lab or office, you will be responsible for the blood draw fee.

This program does not cover or pay for follow-up consults and diagnostic procedures (e.g., imaging, biopsies, other laboratory tests, etc.) that your healthcare provider may recommend for you in the event of a “Cancer Signal Detected” Galleri test result. You
may incur cost-share expenses such as copays, deductibles, and coinsurance. Please contact your health insurer to determine covered expenses and your potential costs related to follow-up procedures that your provider may recommend.

Cancer screening with Galleri can make a difference

Galleri looks for many deadly cancers before symptoms appear from a single blood draw and identifies a unique “fingerprint” of 50+ cancers, including many without a recommended screening available today.
  • Cindy testimonial preview

    Patient testimonial: Cindy

    Cancer Signal Detected

  • Jonathan Testimonial Lyphoma

    Patient testimonial: Jonathan

    Cancer Signal Detected

  • Rich testimonials

    Patient testimonial: Rich

    Cancer Signal Detected

  • Mary patient vid

    Patient testimonial: Mary

    Cancer Signal Detected

  • Roger testimonial

    Patient testimonial: Roger

    Cancer Signal Detected

  • Valerie

    Patient testimonial: Valerie

    Cancer Signal Detected

  • Patient story video still closeup of Tami

    Patient testimonial: Tami

    No Cancer Signal Detected

  • patient story video still of Keith and his wife on a walk

    Patient testimonial: Keith

    No Cancer Signal Detected

  • Jennifer Testimonial poster

    Patient testimonial: Jennifer

    No Cancer Signal Detected

  • Rich S Taci

    Patient testimonial: Rich & Staci

    Cancer Signal Detected

  • Oncologist perspective

    Oncologist Perspectives

1 / 11

What do Galleri test results mean?


What does a “Cancer Signal Detected” result mean?


The Galleri test looked for a cancer signal in your blood sample and found one. About 1 out of every 100 tests has a Cancer Signal Detected result.4*

This result also include one or two predictions of the tissue type or organ associated with the cancer signal, called ​"Cancer Signal Origin."

In a clinical study, around 4 out of 10 people with this result were diagnosed with cancer after diagnostic testing.4

*In the PATHFINDER study2, out of 6,578 participants tested with Galleri, 58 had a Cancer Signal Detected result.
 

cancer signal origin image

Other: Anus, Bone and Soft Tissue, Head and Neck, Lymphoid Lineage, Melanocytic Lineage, Myeloid Lineage, Neuroendocrine Cells of Lung or other Organs, Plasma Cell Lineage, Thyroid Gland, Uterus.

Cancer signal detected thumb
NEXT STEPS

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider to confirm cancer.

What does a “No Cancer Signal Detected” result mean?


The Galleri test looked for a cancer signal in your blood sample and did not find one.

In a clinical study, less than 2% of individuals with a No Cancer Signal Detected result had cancer.1,4
 

This result does not completely rule out the possibility of cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. This result does not predict whether you will develop cancer in the future.

Cancer signal not detected thumb
NEXT STEPS

Continue with any routine cancer screenings your healthcare provider recommends. Do not ignore cancer signs or symptoms if they occur as this could lead to a delayed diagnosis.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Please note - there is a copay to access the test. The Galleri test is available by prescription only. This program does not cover or pay for follow-up consults and diagnostic procedures (e.g., imaging, biopsies, other laboratory tests, etc.) that your healthcare provider may recommend for you in the event of a “Cancer Signal Detected” Galleri test result. You may incur cost-share expenses such as copays, deductibles, and coinsurance. Please contact your health insurer to determine covered expenses and your potential costs related to follow-up procedures that your provider may recommend.

Frequently Asked Questions

The Galleri test is available to eligible Priority Health Medicare Advantage members* who meet the eligibility requirements. The Galleri test is available by prescription only.

Eligibility Requirements:

  • Individuals 65 years or older who are actively enrolled in one of the following 2025 Priority Health Medicare plans:
     
    • PriorityMedicare Thrive - $150 copay (a value of $799)
    • PriorityMedicare Thrive Plus - $75 copay (a value of $874)
  • Not currently undergoing active cancer treatment, though history of cancer^ with treatments completed at least 3 years ago is permitted

AND must also have AT LEAST ONE of the following clinical risk factors:

  • Diagnosis of HPV
  • Currently smokes or history of smoking
  • Elevated body mass index
    • Female ≥ 30 kg/m2
    • Male ≥ 35 kg/m2

* Eligible members can request the Galleri test once every two years.
^ excludes basal or squamous cell carcinoma of the skin

To access the Galleri test benefit, you must request the test through Recuro Health, an independent telemedicine healthcare provider partnered with GRAIL, via the test request process on Galleri.com/PriorityHealth.
 
The Recuro Health provider will review your request and order the test, if appropriate. The Galleri test is available by prescription only.

Individuals 65 years or older who are actively enrolled in one of the following 2025 Priority Health Medicare plans:

  • PriorityMedicare Thrive - $150 copay
    (a value of $799)
  • PriorityMedicare Thrive Plus - $75 copay
    (a value of $874)

Yes, if you have a history of cancer, you may be eligible for the Galleri test. You must not currently be receiving active cancer treatment and you must have completed cancer treatment at least 3 years ago.*


*excludes basal or squamous cell carcinoma of the skin

GRAIL is a healthcare company focused on improving health by pioneering new technologies for early cancer detection. GRAIL is the company that manufactures the Galleri multi-cancer early detection test. You may receive information or communications from GRAIL or Galleri about your benefit or the Galleri test.

Under this program, eligible members can request the Galleri test once every two years.

To access the Galleri test under your benefit, you must request the test online at Galleri.com/PriorityHealth through an independent telemedicine provider from Recuro Health.

When you request the test, you are given the option to enter your primary healthcare provider’s contact information; if you provide this, your test result will be automatically shared with your primary healthcare provider if a cancer signal is detected. If no cancer signal is detected, you can share the results with your provider, but GRAIL will not automatically send it.

 
Please note, the blood draw associated with Galleri must occur on a date you are covered under this employee benefit. Members are responsible for the full cost of the test when obtained via any other means such as a personal physician or when the blood draw date of service occurs after Priority Health benefit coverage has ended.

Under this program, eligible members can request the Galleri test once every two years.

Galleri is a multi-cancer early detection test that can be taken as a simple annual blood test and screens for many of the deadliest cancers before they become symptomatic. The Galleri test gives you more control when it comes to cancer.

In a clinical study, the Galleri test was able to detect a signal shared by more than 50 types of cancer.2 See the list of cancer types study participants had when a cancer signal was detected

Watch a short video to learn more

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Cancers growing in the body shed DNA into the bloodstream.2,5,6 Although there are many types of cancer, the DNA fragments can act like a unique “fingerprint” of cancer. This Galleri test screens for many of the deadliest cancers before they become symptomatic, including those without recommended screening tests.2,7 When there is a Cancer Signal Detected, the results also provide predicted Cancer Signal Origin* to help your healthcare provider determine the next steps for diagnosis.

*GRAIL, Inc. Data on file: VV-TMF-59592

Watch a short video to learn more

More than 1 in 3 people will develop cancer in their lifetime.8 People over the age of 50 have a 13 times higher risk for cancer than those under 50. Cancer risk increases for everyone as they age, regardless of family history7 — only 5% to 10% of cancers are inherited.9,10

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older.

Talk to your provider about your risk for cancer, and whether the Galleri test is right for you.

Learn more about cancer risk

In a clinical study, Galleri detected a signal shared by over 50 types of cancer —including some fast-spreading and aggressive cancers responsible for approximately two-thirds of cancer deaths.2 Galleri is a cancer screening test, meaning it looks for cancer before symptoms appear. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood.

See the list of cancer types study participants had when a cancer signal was detected.2

False positive and false negative results do occur.

Nearly 99% of people who take the Galleri test will receive a No Cancer Signal Detected result. A Cancer Signal Detected result is expected in approximately 1% of Galleri tests in people over 50 years of age. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.5


Some of the ways we measure test accuracy is with positive predictive value (PPV) and a false positive rate. A PPV is the probability that a person with a Cancer Signal Detected test result has cancer. In a recent study the PPV was 43.1% for study participants with a Cancer Signal Detected result who were diagnosed with cancer. The false positive rate was 0.5% for participants without cancer.5

No, a genetic or hereditary risk assessment is a one time only measurement and assesses your future risk of developing cancer. The Galleri test is a point-in-time test that identifies DNA in the bloodstream shed by cancer cells and screens for cancer at the time of testing.

The test is only available in the US at this time. You can request a test through your healthcare provider or on our website through an independent telemedicine provider.

When you’re ready to take the Galleri test, you can schedule your blood draw at a time and place convenient for you:

  • One of our partner labs
  • Your home, office, or any preferred location by a trained technician

Learn more about how your sample is processed at the GRAIL lab by watching the Life of a Galleri Test Sample video.

Once you receive your sample collection kit, please do not break the quality seal on it. The collection kit should be opened by the trained technician who draws your blood sample.

Store the kit at room temperature until your blood draw appointment. The contents are sensitive to extreme temperatures. For example, do not store the collection kit in a car.
To schedule your blood draw visit: Galleri.com/schedule

The trained technician who draws your blood will pack and ship your sample back to the GRAIL laboratory for processing.

No, fasting is not required for the Galleri test.

Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes from a vein in your arm.

If you no longer wish to receive your Galleri test result, please contact your healthcare provider to request a cancellation. If you are not able to reach your healthcare provider or require further assistance, contact GRAIL Customer Service by completing the online form on the Contact Us web page or by calling (833) 694‑2553.

If your test has already been processed by the GRAIL laboratory you will be responsible for the cost of the test.

Your test results can be requested by contacting GRAIL Customer Service by filling out a support request or calling (833) 694‑2553.

The Galleri test detected DNA methylation patterns that are often associated with cancer in your blood sample. About 1 out of every 100 tests has a Cancer Signal Detected result.3

This result will also include a prediction of the tissue type or organ associated with the cancer signal, called a ​Cancer Signal Origin. This helps your doctor determine the next steps for diagnosis.

Results should be interpreted by a healthcare provider. This test result is not a cancer diagnosis and requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider to confirm cancer. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps.

False positive results do occur.

The Galleri test did not detect DNA methylation patterns that are associated with cancer in your blood sample. Nearly 99% of people who use the Galleri test, will receive a No Cancer Signal Detected result.3

This result does not completely rule out the possibility of cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. This result does not predict whether you will develop cancer in the future.

The Galleri test can be taken as an annual blood test. Adding the Galleri test to annual wellness visits allows you to go further with cancer screenings. Ask your healthcare provider when is best to test again.

False negative results do occur.

The Galleri test is intended to be used in addition to — and not replace — other cancer screening tests your healthcare provider recommends. Single-cancer screening tests are recommended because they have been proven to save lives by detecting cancer early. Adding the Galleri test to annual wellness visits allows you to go further with cancer screenings.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood.

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider to confirm cancer. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps.

All results are automatically shared with the provider who ordered the test. If you would like us to fax your result to an additional healthcare provider, contact GRAIL Customer Service and complete the online form on the Contact Us web page or call (833) 694‑2553 to receive instructions on how to complete a results release form.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service:

By email: customerservice@​grail.​com

By telephone: 1-877-GRAILPH (1-877-472-4574)

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. American Cancer Society. Cancer facts & figures 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html [GRAIL, LLC. Data on file: GA-2021-0065]
  2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI: https://doi.org/10.1016/j.annonc.2021.05.806.
  3. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi:10.1016/S0140-6736(23)01700-2
  4. The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to routine screening tests your healthcare provider recommends.
  5. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020 Mar 30;31(6):745-59. doi: 10.1016/j.annonc.2020.02.011
  6. Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016 Jul 8;35:347–76. doi: 10.1007/s10555-016-9629-x
  7. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings. [cited 2023 Oct 23].
  8. American Cancer Society. Lifetime risk of developing or dying from cancer. [cited 2023 Oct 11]. https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html
  9. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER Research Limited-Field Data, 21 Regs, 2020 Nov Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released 2021 Apr, based on the 2020 Nov submission. [Risk Factor Data on file: American Cancer Society Cancer Prevention Studies II/III.]
  10. NIH, National Cancer Institute. Genetic testing for inherited cancer susceptibility syndromes. [cited 2023 Mar 3]. https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet